BRP
Metabolic / fat loss
Appetite, glucose, weight, and metabolic regulation
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Incretin / metabolic peptide or small molecule
- Primary mechanism
- Incretin/amylin/glucagon-axis receptor modulation
- Primary market use
- Metabolic / fat loss
Pharmacology
- Molecular weight (Da)
- 1540.88
- Oral bioavailability
- Route-dependent / verify
- Half-life
- ~12 h–7 days depending analog/acylation
- Route tags
- SubQ; Injectable; route-dependent
- Evidence level
- MCE product listing / research chemical signal
- Clinical status
- Research chemical/reference listing
- Value-for-money score
- 8 / 10
Reported protocol signal
No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Stackability
Commonly compared/stacked in metabolic and body-composition protocols; verify redundancy and risk.
Notes
BRP (BRINP2-related peptide) TFA is a 12-peptide derived from BRINP2 that can cross the blood-brain barrier. BRP TFA induces the central activation of FOS in neuronal cells via the cAMP-PKA-CREB signaling pathway. BRP TFA exerts anorectic and anti-obesity effects without triggering nausea or aversive responses. The action of BRP TFA is independent of the leptin , GLP-1 receptor and melanocortin 4 receptor pathways. BRP TFA is applicable to obesity-related research.